Last reviewed · How we verify
L-Carnitine ( high dose)
L-Carnitine ( high dose) is a Amino acid supplement / Metabolic agent Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Primary carnitine deficiency, Secondary carnitine deficiency in chronic kidney disease, Muscle weakness and fatigue associated with carnitine deficiency.
L-Carnitine facilitates the transport of long-chain fatty acids into mitochondria for β-oxidation, enhancing cellular energy production.
L-Carnitine facilitates the transport of long-chain fatty acids into mitochondria for β-oxidation, enhancing cellular energy production. Used for Primary carnitine deficiency, Secondary carnitine deficiency in chronic kidney disease, Muscle weakness and fatigue associated with carnitine deficiency.
At a glance
| Generic name | L-Carnitine ( high dose) |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Amino acid supplement / Metabolic agent |
| Target | Carnitine palmitoyltransferase (CPT) system |
| Modality | Small molecule |
| Therapeutic area | Metabolic disorders, Cardiovascular, Neurology |
| Phase | FDA-approved |
Mechanism of action
L-Carnitine is an amino acid derivative that acts as a carrier molecule, binding to fatty acyl-CoA and transporting them across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system. This process is essential for mitochondrial fatty acid oxidation and ATP generation. High-dose supplementation aims to increase energy availability in tissues with high metabolic demand or carnitine deficiency.
Approved indications
- Primary carnitine deficiency
- Secondary carnitine deficiency in chronic kidney disease
- Muscle weakness and fatigue associated with carnitine deficiency
- Heart failure (adjunctive therapy)
Common side effects
- Gastrointestinal upset (nausea, diarrhea, abdominal discomfort)
- Myalgia or muscle pain
- Headache
- Fishy body odor (from trimethylamine metabolite)
Key clinical trials
- Effects of Carnitine Supplementation on Exercise-Induced Muscle Damage: A Randomized Controlled Trial (NA)
- Assessment of the Efficacy of Carnipure® AAS on Body Composition, Muscle Thickness, and Strength Adaptations in Healthy Men (NA)
- The Efficacy of L-Carnitine in the Management of Acute Carbon Monoxide Poisoning (PHASE2)
- High-dose L-Carnitine and Diaphragmatic Function Assessed by Ultrasonography in Patients With Respiratory Failure. (PHASE4)
- Oxidative Stress In Semen And Male Infertility (PHASE4)
- Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Carnitine ( high dose) CI brief — competitive landscape report
- L-Carnitine ( high dose) updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about L-Carnitine ( high dose)
What is L-Carnitine ( high dose)?
How does L-Carnitine ( high dose) work?
What is L-Carnitine ( high dose) used for?
Who makes L-Carnitine ( high dose)?
What drug class is L-Carnitine ( high dose) in?
What development phase is L-Carnitine ( high dose) in?
What are the side effects of L-Carnitine ( high dose)?
What does L-Carnitine ( high dose) target?
Related
- Drug class: All Amino acid supplement / Metabolic agent drugs
- Target: All drugs targeting Carnitine palmitoyltransferase (CPT) system
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Metabolic disorders, Cardiovascular, Neurology
- Indication: Drugs for Primary carnitine deficiency
- Indication: Drugs for Secondary carnitine deficiency in chronic kidney disease
- Indication: Drugs for Muscle weakness and fatigue associated with carnitine deficiency
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing